Strides Arcolab has received approval from the US health regulator to market a generic carboplatin injection for the treatment of ovarian cancer.
Onco Therapies Ltd, a wholly-owned subsidiary of the company, has received the United States Food and Drug Administration (USFDA) approval for carboplatin injections, Strides Arcolab said in a statement today.
The approval by the USFDA is for carboplatin injections in strengths of 10 mg/mL, packaged in 50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL and 600 mg/60 mL multi-dose vials.
“Carboplatin is part of the oncology portfolio licensed to Pfizer in January 2010 for the US market and is expected to be launched shortly,” Strides Arcolab said.
According to IMS data of June 11, the US market for generic carboplatin is worth nearly $35 million. Carboplatin injections are indicated for the treatment of advanced ovarian cancer, the statement added.
Shares of Strides Arcolab ended the session on the BSE today at Rs 416.85 apiece, up 1.39 per cent from their previous close.